Speaker illustration

Professor Young-Hoon Jeong

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong (Korea (Republic of))

Member of:

European Society of Cardiology
EAPCI

I have been concerned about individualized antithrombotic treatment and pharmacogenetics. My initial main topic was “ACCEL” series, which ment “ACCELerate”, or “ACCELerando”. I have been devoted to optimization of antithrombotic therapy, especially in East Asian population. This effort can suggest the concept of "East Asian Paradox". Furthermore, the concept of thrombogenecity and pleiotrophic effect of platelet function including wound healing process have been the main topics in the recent days. I have the important academic roles in Thrombosis research field. I have the role of President in Platelet-Thrombosis Research Group and a member of ESC Working Group of Thrombosis. I have studied many clinical issues reagrding the ethnic difference of CV disease and underlysing mechanism related with thrombogenicity.

Relationship between serial c-reactive protein levels and cardiovascular events in East asian patients treated with percutaneous coronary intervention

Event: ESC Congress 2018

Topic: Epidemiology, Prognosis, Outcome

Session: Best Posters in new insights in the assessment of the long-term risk in coronary disease

Thumbnail

Influence of amlodipine on antiplatelet effect of clopidogrel in patients treated with percutaneous coronary intervention: result of the randomized, prospective, two-period, crossover, ACCEL-CCB trial

Event: ESC CONGRESS 2017

Topic: Thrombosis and platelets

Session: Best Posters in antiplatelet agents in acute coronary syndromes

Thumbnail

A randomised, double-blind, placebo controlled trial to evaluate the effect of adjunctive cilostazol on endothelial progenitor cell mobilization in AMI patients: the result of the ACCEL-EPISODE trial

Event: ESC CONGRESS 2016

Topic: Adjunctive medical therapy

Session: Adjunctive medical therapy in coronary artery disease

Thumbnail

This platform is supported by

logo Novo Nordisk